このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Remimazolam-Flumazenil Versus Sevoflurane for Hysteroscopic Day Surgery

2026年6月17日 更新者:Jiwon Han、Chung-Ang University Gwangmyeong Hospital

Remimazolam With Planned Flumazenil Reversal Versus Sevoflurane-based Balanced Anesthesia for Hysteroscopic Day Surgery: A Randomized Controlled Trial

This prospective, single-center, randomized controlled trial aims to compare remimazolam anesthesia with planned flumazenil reversal and sevoflurane-based balanced anesthesia in adult women undergoing ambulatory hysteroscopic surgery.

Participants will be randomly assigned in a 1:1 ratio to receive either remimazolam for induction and maintenance followed by flumazenil reversal or propofol induction followed by sevoflurane-based balanced anesthesia. The primary outcome is anesthesia-controlled time, defined as the sum of induction time and emergence time. Secondary outcomes include recovery profiles, postoperative symptoms, quality of recovery, hemodynamic stability, and the incidence of re-sedation. The study will evaluate whether a remimazolam-flumazenil strategy can improve operating room efficiency while maintaining recovery quality and safety comparable to conventional sevoflurane-based anesthesia in the ambulatory surgery setting.

調査の概要

詳細な説明

Ambulatory surgery has become an increasingly important component of modern healthcare systems because it enables rapid recovery, early discharge, efficient utilization of hospital resources, and improved patient satisfaction. The success of ambulatory surgery depends largely on the ability to provide anesthetic care that ensures rapid emergence, minimal postoperative symptoms, and timely discharge without compromising patient safety. Hysteroscopic surgery is one of the most commonly performed ambulatory gynecologic procedures and therefore represents an ideal model for evaluating anesthetic strategies designed to optimize perioperative efficiency and recovery.

Sevoflurane-based balanced anesthesia, typically consisting of intravenous induction followed by maintenance with a volatile anesthetic agent, remains one of the most widely used anesthetic techniques for ambulatory surgery. Although this approach provides reliable hypnosis and favorable surgical conditions, recovery is dependent on anesthetic elimination and individual patient characteristics. Furthermore, volatile anesthetics may contribute to postoperative nausea and vomiting, which remain among the most common causes of delayed discharge and patient dissatisfaction following ambulatory procedures.

Remimazolam is a novel ultra-short-acting benzodiazepine anesthetic that is rapidly metabolized by nonspecific tissue esterases. Compared with conventional anesthetic agents, remimazolam demonstrates predictable pharmacokinetics, limited accumulation, reduced respiratory depression, and favorable hemodynamic stability. Several clinical studies have shown that remimazolam may reduce the incidence and severity of hypotension compared with propofol while providing effective hypnosis for general anesthesia. However, concerns remain regarding delayed awakening and the possibility of residual sedation, particularly in short ambulatory procedures where rapid recovery is essential.

A unique characteristic of remimazolam is the availability of flumazenil, a specific benzodiazepine receptor antagonist capable of rapidly reversing its sedative effects. Planned administration of flumazenil at the end of surgery may allow faster and more predictable emergence than spontaneous recovery alone. Despite this theoretical advantage, evidence supporting a structured remimazolam-flumazenil anesthetic strategy in ambulatory surgery remains limited. Most previous investigations have focused on pharmacodynamic comparisons between remimazolam and propofol, whereas direct comparisons with inhalational balanced anesthesia have been relatively scarce. In addition, few studies have evaluated outcomes that are directly relevant to operating room efficiency and perioperative workflow.

The concept of anesthesia-controlled time has been proposed as a clinically meaningful measure of anesthetic efficiency because it incorporates both induction and emergence phases of anesthesia. Unlike isolated measurements of induction time or awakening time, anesthesia-controlled time reflects the overall contribution of anesthetic management to operating room utilization and turnover. Reductions in anesthesia-controlled time may improve operating room throughput, increase institutional efficiency, and facilitate patient flow in ambulatory surgery centers.

This prospective, single-center, randomized controlled trial is designed to compare remimazolam anesthesia with planned flumazenil reversal and sevoflurane-based balanced anesthesia in adult women undergoing ambulatory hysteroscopic surgery. Eligible participants will be randomly assigned in a 1:1 ratio to receive either remimazolam for induction and maintenance followed by flumazenil reversal at the end of surgery or propofol induction followed by sevoflurane-based balanced anesthesia. Standardized perioperative management protocols will be applied to both groups, including opioid administration, neuromuscular blockade, supraglottic airway management, and electroencephalographic monitoring using the Patient State Index (PSI).

The primary outcome will be anesthesia-controlled time, defined as the sum of induction time and emergence time. Induction time will be measured from initiation of the anesthetic agent to successful placement of the supraglottic airway device, while emergence time will be measured from discontinuation of the primary anesthetic agent to removal of the airway device. This endpoint was selected because it directly reflects operating room efficiency and represents a clinically relevant outcome in ambulatory surgical practice.

Secondary outcomes will evaluate multiple aspects of recovery quality and patient safety. These outcomes include time to achieve an Aldrete score of at least 9, duration of stay in the post-anesthesia care unit, postoperative nausea and vomiting, sore throat, surgical pain, shivering, dizziness, vasopressor requirements, and quality of recovery assessed using the validated Quality of Recovery-15 (QoR-15) questionnaire. The incidence of re-sedation will be evaluated using the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) scale together with electroencephalographic monitoring data. Additional recovery variables, including time to eye opening, time to PSI recovery, and time to airway device removal, will also be assessed.

The investigators hypothesize that remimazolam anesthesia with planned flumazenil reversal will reduce anesthesia-controlled time and improve perioperative efficiency while maintaining recovery quality and safety comparable to conventional sevoflurane-based balanced anesthesia. The findings of this study may provide clinically relevant evidence regarding the optimal anesthetic strategy for ambulatory hysteroscopic surgery and may support broader implementation of remimazolam-based anesthesia in short-duration surgical procedures.

研究の種類

介入

入学 (推定)

124

段階

  • フェーズ 4

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Jiwon Han, MD, PhD
  • 電話番号:+82-10-3447-1988
  • メール:yesuroon@gmail.com

研究連絡先のバックアップ

研究場所

    • Gyeonggi-do
      • Gwangmyeong、Gyeonggi-do、韓国、14353
        • Chung-Ang University Gwangmyeong Hospital
        • コンタクト:
        • コンタクト:
        • 主任研究者:
          • Jiwon Han, MD, PhD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  • Female patients aged 20 years or older.
  • Scheduled to undergo ambulatory hysteroscopic surgery under general anesthesia.
  • Able to provide written informed consent.
  • American Society of Anesthesiologists (ASA) physical status I-III.

Exclusion Criteria:

  • Known hypersensitivity to benzodiazepines, remimazolam, or flumazenil.
  • Chronic use of benzodiazepines or opioids.
  • Severe hepatic dysfunction (Child-Pugh class B or C).
  • Severe renal dysfunction (estimated glomerular filtration rate <30 mL/min/1.73 m²).
  • Epilepsy or other significant neurologic disorders.
  • Pregnancy or breastfeeding.
  • Body mass index (BMI) ≥35 kg/m².
  • Severe obstructive sleep apnea.
  • Uncontrolled serious systemic disease that may preclude ambulatory surgery.
  • Refusal or inability to provide informed consent.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
実験的:remimazolam-fumazeil group
Participants will receive remimazolam for induction and maintenance of general anesthesia. At the end of surgery, flumazenil will be administered to facilitate rapid emergence from anesthesia. Standardized perioperative management, including fentanyl, rocuronium, supraglottic airway management, and postoperative monitoring, will be applied.
Remimazolam will be administered at 12 mg/kg/h for induction of anesthesia until loss of consciousness, followed by maintenance at 1-2 mg/kg/h until the end of surgery.
Flumazenil 0.5 mg will be administered intravenously at the end of surgery to reverse remimazolam-induced sedation. Additional doses of 0.2 mg may be administered if necessary, up to a maximum total dose of 1.0 mg.
アクティブコンパレータ:sevoflurane group
Participants will receive propofol for induction of general anesthesia followed by maintenance with sevoflurane-based balanced anesthesia. Standardized perioperative management will be applied similarly to the experimental group.
Sevoflurane will be administered at 1.5-3.5 vol% for maintenance of anesthesia following propofol induction. At the end of surgery, sevoflurane administration will be discontinued and washout will be facilitated using fresh gas flow of 6 L/min.
Propofol 2 mg/kg will be administered intravenously for induction of anesthesia before initiation of sevoflurane maintenance.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Anesthesia-Controlled Time
時間枠:From initiation of anesthesia to removal of the supraglottic airway device during emergence from anesthesia, assessed up to 120 minutes.
Anesthesia-controlled time is defined as the sum of induction time and emergence time. Induction time is measured from initiation of the anesthetic agent to successful placement of the supraglottic airway device. Emergence time is measured from discontinuation of the primary anesthetic agent to removal of the supraglottic airway device.
From initiation of anesthesia to removal of the supraglottic airway device during emergence from anesthesia, assessed up to 120 minutes.

二次結果の測定

結果測定
メジャーの説明
時間枠
Time to Aldrete Score ≥9
時間枠:Up to 30 minutes after PACU admission
Time required to achieve an Aldrete score of at least 9 following admission to the post-anesthesia care unit (PACU).
Up to 30 minutes after PACU admission
Length of Stay in PACU
時間枠:From admission to the post-anesthesia care unit until discharge from the post-anesthesia care unit, assessed up to 2 hours.
Duration of stay in the post-anesthesia care unit.
From admission to the post-anesthesia care unit until discharge from the post-anesthesia care unit, assessed up to 2 hours.
Postoperative Symptoms During the Acute Recovery Phase
時間枠:During PACU stay, up to 30 minutes after PACU admission
Postoperative symptoms during the acute recovery phase will be assessed in the post-anesthesia care unit using 11-point Numeric Rating Scales. Symptoms include nausea, sore throat, surgical pain, shivering, and dizziness, each scored from 0 to 10, with 0 indicating no symptom and 10 indicating the worst imaginable symptom. The occurrence of vomiting will also be recorded.
During PACU stay, up to 30 minutes after PACU admission
Quality of Recovery-15 (QoR-15) Score
時間枠:24 hours after surgery
Quality of recovery assessed using the Quality of Recovery-15 (QoR-15) questionnaire. The QoR-15 is a validated patient-reported outcome measure ranging from 0 to 150 points, with higher scores indicating better postoperative recovery.
24 hours after surgery
Incidence of Re-sedation
時間枠:From PACU admission through discharge from the ambulatory surgery center, assessed up to 8 hours after surgery.
Occurrence of re-sedation defined as a Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score ≤3.
From PACU admission through discharge from the ambulatory surgery center, assessed up to 8 hours after surgery.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Jiwon Han、Chung-Ang University Gwangmyeong Hospital

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年6月1日

一次修了 (推定)

2028年6月1日

研究の完了 (推定)

2028年6月1日

試験登録日

最初に提出

2026年6月15日

QC基準を満たした最初の提出物

2026年6月17日

最初の投稿 (実際)

2026年6月23日

学習記録の更新

投稿された最後の更新 (実際)

2026年6月23日

QC基準を満たした最後の更新が送信されました

2026年6月17日

最終確認日

2026年6月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する